Methods for minimally invasive, non-permanent occlusion of a uterine artery

Abstract

Non-permanent occlusion of the uterine arteries is sufficient to cause the demise of uterine myomata without unnecessarily exposing other tissues and anatomical structures to hypoxia attendant to prior permanent occlusion techniques. A therapeutically effective transient time of occlusion of a uterine artery to treat uterine fibroid tumors is from 1 hours to 24 hours, and preferably is at least about 4 hours. A therapeutically effective temporary time of occlusion of a uterine artery to treat uterine fibroid tumors is from 1 day (24 hours) to 7 days (168 hours), and preferably is about 4 days (96 hours). By invaginating the tissues of the vaginal wall up to or around a uterine artery, collapse of the uterine artery can be achieved without penetrating tissue of the patient.

Description

[0001] This application is a divisional of copending application Ser. No. 09 / 908,815 filed Jul. 20, 2001, which is a continuation of co-pending application Ser. No. 09 / 556,934 filed Apr. 20, 2000, now U.S. Pat. No. 6,550,482 and which claims priority to provisional application Ser. No. 60 / 279,477 filed Mar. 28, 2001, all of which are incorporated herein by reference in their entirety.BACKGROUND OF THE INVENTION [0002] 1. Field of the Invention [0003] The present invention relates generally to the treatment of disorders which receive blood flow from the uterine arteries, and more particularly to methods for the non-permanent occlusion of the uterine artery or arteries, including for use in treating uterine myomata (fibroids), dysfunctional uterine bleeding (DUB), post partum hemorrhaging (PPH), and uterine bleeding associated with cesarian section surgery. [0004] 2. Brief Description of the Related Art [0005] Hysterectomy (surgical removal of the uterus) is performed on approximately...

AI Technical Summary

Problems solved by technology

Hysterectomy for treating uterine fibroid disorders, though effective, has many undesirable characteristics.

The undesirable characteristics of hysterectomy include a known mortality rate of 0.5 deaths per 1000 hysterectomies.

Consequently, it is difficult to know which fibroid is causing symptoms to the patient (bleeding, pain, and bulk effects on adjacent organs).

Clearly, the strategy of identifying which individual fibroid is causing symptoms (when there are often many), finding that fibroid, and then either removing or destroying that individual fibroid is a rather complex strategy.

Second, fibroids live a tenuous vascular life with very little ability to recruit a new blood supply from the host when the primary blood supply is compromised.

This procedure has been performed laparoscopically and requires a great deal of surgical skill to access, identify, dissect, and ligate the uterine arteries.

This requirement for high skill and a full surgical approach has limited the use of surgical ligation of the uterine arteries as a clinical alternative for uterine fibroid treatment.

Heretofore, this inherent characteristic of these tissues has not been utilized in the treatment of myomata, or for accessing the uterine artery.

The difficulty and cost associated with the use of traditional transvascular access, and the possibility of infection and surgical complication associated with dissection, render these prior techniques unacceptable.

PPH and cesarian section-related bleeding can be a dangerous if not quickly and adequately controlled, which may require a fast surgical response, from which the patient may suffer from associated trauma of the surgery.

This ligation task can be very laborious and time-consuming, as the arteries are dissected and ligated by the surgeon, and have associated complications.

Images